Cue Biopharma is trading 6.9% up at $28.08, continuing a volatile reaction to its August 14, 2026 second-quarter results and recent pipeline developments.
- Reported $7.88 million in quarterly revenue and submitted an FDA investigational new drug application for CUE-221 in food allergy.
- Completed a $50 million private placement; biotechnology is down 2.47% and major U.S. indexes are lower.
- No new August 20 company announcement was found, so the move appears driven mainly by ongoing company-specific repricing and high volatility.